Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion

Clin Breast Cancer. 2018 Jun;18(3):e267-e270. doi: 10.1016/j.clbc.2017.11.017. Epub 2017 Nov 28.

Authors

Affiliations

¹ Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
² Department of Pathology, Rabin Medical Center, Petah Tikva, Israel.
³ Loxo Oncology Inc, South San Francisco, CA.
⁴ Foundation Medicine, Cambridge, MA.
⁵ Sorokoa Cancer Institute, Ben Gurion University, Beer-Sheva, Israel. Electronic address: [email protected].

PMID: 29233640
DOI: 10.1016/j.clbc.2017.11.017

No abstract available

Keywords: NGS; NTRK3; SBC; TNBC; Targeted therapy.

Publication types

Case Reports

MeSH terms

Adult
Biopsy
Bone Neoplasms / diagnostic imaging
Bone Neoplasms / drug therapy*
Bone Neoplasms / secondary
Breast / pathology
Breast / surgery
Breast Neoplasms / pathology
Breast Neoplasms / therapy*
Chemotherapy, Adjuvant / methods
Female
Humans
Lymphatic Metastasis / diagnostic imaging
Mastectomy
Oncogene Proteins, Fusion / metabolism*
Palliative Care / methods
Pleural Effusion, Malignant / diagnostic imaging
Pleural Effusion, Malignant / drug therapy*
Positron Emission Tomography Computed Tomography
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Treatment Outcome
Treatment Refusal
Triple Negative Breast Neoplasms / pathology
Triple Negative Breast Neoplasms / therapy*

Substances

ETV6-NTRK3 fusion protein, human
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
larotrectinib